Insider · CIK 0002066784
Nicholas A.J. Botwood
Files at SNDX (Syndax Pharmaceuticals Inc). First filing May 19, 2025, latest Jun 12, 2026.
In brief
Nicholas A.J. Botwood files SEC Form 4 as officer at SNDX (Syndax Pharmaceuticals Inc). Since May 19, 2025, Nicholas A.J. Botwood has reported 1 open-market buy worth $106k and 1 open-market sell worth $1.2M, the latest filed on Jun 12, 2026.
A track record needs three past buys with six months of prices behind them; Nicholas A.J. Botwood has 0, so none is measured yet.
The newest scored trade: sold $1.2M of SNDX on Jun 11, 2026, filed Jun 12, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $1.2M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SNDX: Syndax Pharmaceuticals Inc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Syndax Pharmaceuticals Inc | $1.2M 65,515 shares | -69% | +105% from low-29% from high | |
| 68Notable | Syndax Pharmaceuticals Inc | $106k 11,765 shares | +50% | +1% from low-59% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | 31,235 0.04% of outstanding | $567k | Jun 12, 2026 | $609k |
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | 34,280 0.04% of outstanding | $609k | Jun 11, 2026 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | MOption exercise Common Stock10b5-1 | +22,515 | $13.82 | $311k | 95,165 | Jun 12, 2026 |
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | SOpen-market sale Common Stock10b5-1 | -34,280 | $18.00 | $617k | 60,885 | Jun 12, 2026 |
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | MOption exercise Common Stock10b5-1 | +31,235 | $13.82 | $432k | 92,120 | Jun 12, 2026 |
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | SOpen-market sale Common Stock10b5-1 | -31,235 | $18.14 | $567k | 60,885 | Jun 12, 2026 |
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | MOption exercise Stock options (Right to buy)derivative10b5-1 | +22,515 | $0.00 | $0 | 0 | Jun 12, 2026 |
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | MOption exercise Stock options (Right to buy)derivative10b5-1 | +31,235 | $0.00 | $0 | 0 | Jun 12, 2026 |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 59,165 | Feb 6, 2026 |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Common Stock | +36,000 | $0.00 | $0 | 95,165 | Feb 6, 2026 |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Stock Options (Right to buy)derivative | +144,700 | $20.43 | $3.0M | 144,700 | Feb 6, 2026 |
| May 16, 2025 | SNDX Syndax Pharmaceuticals Inc | POpen-market purchase Common Stock | +11,765 | $9.00 | $106k | 35,165 | May 19, 2025 |
Questions about Nicholas A.J. Botwood
Answered from the filings on this page, as of the latest one.
Is Nicholas A.J. Botwood buying or selling?
In the last 12 months Nicholas A.J. Botwood reported 0 open-market buys worth $0 and 1 open-market sell worth $1.2M on SEC Form 4; the latest was sold $1.2M of SNDX on Jun 11, 2026. Grants, option exercises and tax withholding are not counted.
How did Nicholas A.J. Botwood's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicholas A.J. Botwood has 0.
Where does Nicholas A.J. Botwood file Form 4?
Nicholas A.J. Botwood has filed Form 4 at SNDX (Syndax Pharmaceuticals Inc) as Head of R&D, CMO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.